State of New Jersey Common Pension Fund D Boosts Stock Holdings in Becton Dickinson and Co (NYSE:BDX)
State of New Jersey Common Pension Fund D grew its position in shares of Becton Dickinson and Co (NYSE:BDX) by 27.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 140,000 shares of the medical instruments supplier’s stock after buying an additional 30,000 shares during the quarter. State of New Jersey Common Pension Fund D owned 0.05% of Becton Dickinson and worth $35,281,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently bought and sold shares of the company. Harvest Group Wealth Management LLC bought a new stake in shares of Becton Dickinson and in the 1st quarter worth about $25,000. Hexavest Inc. purchased a new position in Becton Dickinson and in the second quarter worth $28,000. Pinnacle Financial Partners Inc. purchased a new position in Becton Dickinson and in the first quarter worth $29,000. RPG Investment Advisory LLC purchased a new position in Becton Dickinson and in the first quarter worth $32,000. Finally, Aspire Private Capital LLC purchased a new position in Becton Dickinson and in the fourth quarter worth $39,000. Hedge funds and other institutional investors own 84.80% of the company’s stock.
Several research analysts recently issued reports on BDX shares. ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. Barclays cut shares of Buckeye Partners from an “overweight” rating to an “equal weight” rating in a research note on Monday, May 13th. Zacks Investment Research lowered shares of GreenTree Hospitality Group from a “buy” rating to a “hold” rating in a report on Monday, May 20th. Raymond James set a C$1.00 target price on shares of Orezone Gold and gave the stock an “outperform” rating in a report on Friday, June 28th. Finally, Wells Fargo & Co lowered their target price on shares of Nevro from $75.00 to $70.00 and set an “outperform” rating for the company in a report on Monday, May 13th. Five analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Becton Dickinson and presently has a consensus rating of “Buy” and an average target price of $263.58.
Becton Dickinson and (NYSE:BDX) last released its earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.02. The company had revenue of $4.20 billion for the quarter, compared to the consensus estimate of $4.25 billion. Becton Dickinson and had a net margin of 5.88% and a return on equity of 14.58%. Becton Dickinson and’s revenue was down .6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.65 EPS. As a group, equities research analysts anticipate that Becton Dickinson and Co will post 11.68 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 1.20%. The ex-dividend date is Friday, September 6th. Becton Dickinson and’s dividend payout ratio (DPR) is currently 27.97%.
In other news, EVP Samrat S. Khichi sold 16,085 shares of the company’s stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $234.68, for a total value of $3,774,827.80. Following the sale, the executive vice president now directly owns 12,608 shares of the company’s stock, valued at approximately $2,958,845.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Betty D. Larson sold 1,700 shares of the company’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $224.97, for a total transaction of $382,449.00. Following the completion of the sale, the executive vice president now directly owns 11,493 shares in the company, valued at $2,585,580.21. The disclosure for this sale can be found here. Insiders sold a total of 21,154 shares of company stock worth $4,955,775 over the last ninety days. Insiders own 0.12% of the company’s stock.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Article: What is included in the gross domestic product?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.